Inicio › Leucemia mielógena aguda › Minnesota

Ensayos clínicos de Leucemia mielógena aguda en Minnesota

28 estudios sobre Leucemia mielógena aguda buscan participantes en Minnesota.

Ciudades en Minnesota

Texto oficial del estudio (inglés)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
y 9 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Minnesota, Minneapolis
HealthPartners Cancer Center at Regions Hospital (MN), Saint Paul

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
y 10 más

ReclutandoFase 2

Edades de 18 a 59 · Todos los sexos · Actualizado el 9 nov 2026 · NCT05554406

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Sanford Joe Lueken Cancer Center, Bemidji

ReclutandoFase 2

Edades de 60 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Riverwood Healthcare Center, Aitkin
Mayo Clinic Health System in Albert Lea, Albert Lea
Essentia Health - Baxter Clinic, Baxter
y 49 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Sanford Joe Lueken Cancer Center, Bemidji
Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
y 10 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT05564390

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Mayo Clinic Hospital - Rochester, Rochester

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT05143996

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
y 9 más

ReclutandoFase 2

Edades de 18 a 59 · Todos los sexos · Actualizado el 28 oct 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
y 9 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06672146

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Mayo Clinic in Rochester, Rochester

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06279572

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

University of Minnesota/Masonic Cancer Center, Minneapolis

ReclutandoFase 1

Hasta los 21 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07012044

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Masonic Cancer Center, Minneapolis

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07008638

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
University of Minnesota/Masonic Cancer Center, Minneapolis
Mayo Clinic in Rochester, Rochester

ReclutandoFase 3

6 Months – 21 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT04293562

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mayo Clinic, Rochester

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Rochester MN-MAYOMN, Rochester

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
University of Minnesota/Masonic Cancer Center, Minneapolis
Mayo Clinic in Rochester, Rochester

ReclutandoFase 1/2

Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Masonic Cancer Center, Minneapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT06594445

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center at University of Minnesota, Minneapolis

ReclutandoFase 2

Hasta los 75 · Todos los sexos · Actualizado el 6 jul 2026 · NCT05805605

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center at University of Minnesota, Minneapolis

ReclutandoFase 2

Hasta los 60 · Todos los sexos · Actualizado el 25 jun 2026 · NCT03314974

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Rochester, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT03017820

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Mark Juckett, MD, Minneapolis

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT07591649

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Masonic Cancer Center at University of Minnesota, Minneapolis

ReclutandoFase 2

Edades de 2 a 75 · Todos los sexos · Actualizado el 16 abr 2026 · NCT07493538

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Mayo Clinic Comprehensive Cancer Center, Rochester

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 abr 2026 · NCT05732103

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

University of Minnesota/Masonic Cancer Center, Minneapolis

ReclutandoEstudio observacional

Hasta los 25 · Todos los sexos · Actualizado el 8 abr 2026 · NCT05014165

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

University of Minnesota Masonic Cancer Center, Minneapolis

ReclutandoFase 2

Hasta los 60 · Todos los sexos · Actualizado el 6 abr 2026 · NCT05735717

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Minnesota, Minneapolis
Mayo Clinic - Rochester, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Mayo Clinic, Rochester

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 feb 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Mayo Clinic, Rochester

ReclutandoSe aceptan voluntarios sanos

Edades de 18 a 120 · Todos los sexos · Actualizado el 25 jul 2025 · NCT05237258

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.